Jacquelyn Sumer
Compliance Officer chez CULLINAN THERAPEUTICS, INC.
Fortune : 2 M $ au 31/03/2024
Profil
Jacquelyn Sumer is currently working as the Secretary, Chief Legal & Compliance Officer at Cullinan Oncology, Inc. She previously worked as the Executive Director & Senior Corporate Counsel at Celgene Corp.
from 2017 to 2018.
She also worked as the Vice President & Assistant General Counsel at Bristol Myers Squibb Co. and as the Chief Legal & Compliance Officer at Genocea Biosciences, Inc. Ms. Sumer completed her undergraduate degree at Bucknell University and her graduate degree at Duke University School of Law.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 22/02/2024 | 94 133 ( 0,22% ) | 2 M $ | 31/03/2024 |
Postes actifs de Jacquelyn Sumer
| Sociétés | Poste | Début |
|---|---|---|
| CULLINAN THERAPEUTICS, INC. | Compliance Officer | 15/08/2022 |
Anciens postes connus de Jacquelyn Sumer
| Sociétés | Poste | Fin |
|---|---|---|
| CELGENE | Director/Board Member | 01/07/2018 |
| BRISTOL-MYERS SQUIBB COMPANY | Corporate Officer/Principal | - |
| GENOCEA BIOSCIENCES, INC. | Compliance Officer | - |
Formation de Jacquelyn Sumer
| Bucknell University | Undergraduate Degree |
| Duke University School of Law | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
| GENOCEA BIOSCIENCES, INC. | Health Technology |
| CULLINAN THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 1 |
|---|---|
Celgene Corp.
 Celgene Corp. BiotechnologyHealth Technology Celgene Corp. is an integrated global biopharmaceutical company, which engages in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases. Its primary commercial stage products include Revlimid, Pomalyst, Imnovid, Otezla, Abraxane, and Vidaza. The company was founded by David Stirling and Sol Barer in 1986 and is headquartered in Summit, NJ. | Health Technology |
